Blog

Jul 10, 2026

Wegovy (semaglutide 2.4mg) produces gastrointestinal side effects in the majority of patients, most commonly nausea, vomiting, diarrhea, and constipation. These occur predominantly during dose escalation and typically diminish at stable maintenance doses. In STEP-1, 44% of participants on Wegovy reported nausea vs. 16% on placebo, and 4.5% discontinued due to GI adverse events. Beyond GI […]

Jul 2, 2026

Retatrutide (LY3437943) is an investigational once-weekly injection from Eli Lilly that activates three metabolic receptors simultaneously — GIP, GLP-1, and glucagon — producing the highest average weight loss ever recorded in a Phase 3 clinical trial. In TRIUMPH-1 (May 2026), adults with obesity on the 12mg dose lost a mean of 28.3% of body weight […]

Jun 25, 2026

“Ozempic face” is the colloquial term for the facial volume loss and skin laxity that some patients experience during rapid weight loss on GLP-1 receptor agonists such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound). The phenomenon is not a side effect of the medication itself but a consequence of rapid fat loss, which depletes subcutaneous […]

Jun 15, 2026

Sermorelin is a 29 amino acid growth hormone-releasing hormone (GHRH) analogue administered as a nightly subcutaneous injection to stimulate the pituitary’s own growth hormone production. Standard starting doses range from 200 to 300 mcg per injection, titrated upward based on IGF-1 response and symptom assessment. Results are gradual: most patients notice improved sleep quality within […]

Jun 8, 2026

Sermorelin and human growth hormone (HGH) both raise growth hormone levels but through fundamentally different mechanisms, with different safety profiles, legal status, and cost implications. HGH is FDA-approved for specific growth hormone deficiency conditions and is a controlled substance requiring strict medical oversight. Sermorelin is a growth hormone-releasing hormone (GHRH) analogue that stimulates the pituitary […]

Jun 4, 2026

Testosterone replacement therapy suppresses sperm production in the majority of men, often to levels incompatible with natural conception. This effect is caused by the suppression of the hypothalamic-pituitary-gonadal (HPG) axis: exogenous testosterone shuts down the FSH and LH signals that drive spermatogenesis in the testes. The suppression is typically reversible after stopping TRT, but recovery […]

May 31, 2026

Neither testosterone pellets nor injections are universally superior — the better choice depends on the individual patient’s lifestyle, tolerance for hormonal fluctuation, cost constraints, and fertility considerations. Injections offer precise dose control, easy adjustment, and lowest cost. Pellets offer convenience and stable levels without weekly administration. Both deliver therapeutic testosterone effectively in confirmed hypogonadism, but […]

May 26, 2026

TRT costs in 2026 range from approximately $30 per month for generic injectable testosterone to over $1,200 per pellet insertion, depending on formulation, provider type, and insurance coverage. Medication is only one component: lab work, physician visits, and supplies add $100 to $400 per month on top of the drug cost in a typical self-pay […]

May 19, 2026

Testosterone replacement therapy improves erectile function in men with confirmed hypogonadism, but it is not a universal treatment for erectile dysfunction. Clinical evidence shows that TRT restores erectile function reliably in men whose ED is caused by testosterone deficiency. In men with normal testosterone, TRT adds little benefit. The key clinical question is not whether […]

May 14, 2026

Low testosterone in men produces a recognizable cluster of symptoms across physical, sexual, and psychological domains. The 15 signs listed here are derived from clinical diagnostic criteria used by the Endocrine Society and reflect the most consistently reported symptoms in hypogonadism research. No single symptom confirms low testosterone. The diagnosis requires laboratory confirmation on at […]

May 10, 2026

Oral semaglutide (Rybelsus) is FDA-approved for type 2 diabetes but not for chronic weight management. The injectable form (Wegovy, 2.4mg weekly) is the only FDA-approved semaglutide formulation for weight loss. Rybelsus produces approximately 4.4% body weight reduction vs. 14.9% with Wegovy in clinical data, primarily because oral bioavailability of semaglutide is approximately 1% compared to […]

May 4, 2026

Tirzepatide (Zepbound) produces greater average weight loss than semaglutide (Wegovy) in head-to-head trial data. The SURMOUNT-5 trial (2025) found tirzepatide reduced body weight by approximately 20.2% vs. 13.7% for semaglutide over 72 weeks. Both are FDA-approved injectable medications for chronic weight management, but they work through different receptor mechanisms, follow different dosing schedules, and carry […]